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Abstract

Keywords

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease (FLD), is a
major public health problem. It is considered to be the hepatic manifestation of the
metabolic syndrome. Chronic inflammation of the liver is an essential key in the
progression from simple hepatic steatosis to steatohepatitis, the evolutionary stage of
fatty liver disease. Moreover, the innate immune system plays a crucial role in the
progression of hepatic inflammation. For this reason, it is of utmost importance to
elucidate the connections between immune mechanisms, Toll-like receptor cytokine
signalling, in order to find new effective treatments.
Further studies are necessary to test theories presented in this paper. The elucidation
of mechanisms underlying the progression of hepatic steatosis towards steatohepatitis is
essential for the development of useful diagnosis and treatment for medical practice.



non-alcoholic steatohepatitis, NASH pathogenesis, immune mechanism, Toll-like
receptors (TLRs), Interleukin-17 (IL-17)

Highlights

 One of the possible mechanisms responsible for the activation of the immune system
through intestinal microbiota is the activation of IL17 axis.
 Another possibility is represented by activation of the TLRs, with further studies being
necessary to clarify these perspectives.
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Introduction
NASH is a disease considered to be the liver
manifestation of the metabolic syndrome (MS) (1). Its
incidence and prevalence are continually increasing
worldwide. The prevalence of NASH in the European
general population is between 20-30% and reaches 90%
among patients with associated obesity (2). NASH has the
potential of advancing to hepatic cirrhosis and increases
the risk of developing hepatocellular carcinoma (HHC)
(2). Due to the alarming increase in the incidence of
obesity associated with NASH and its potential to
progress towards severe chronic hepatic diseases (hepatic
cirrhosis and HHC), it has been estimated that NASH will
become one of the main causes of liver transplant (3).
Sustained inflammatory process in the liver is essential
for the progression from NAFLD to NASH.
Recent medical research has reported important
progress in understanding the immune and inflammatory
mechanisms involved in NASH (4).

Discussions
Hepatic cell population
The liver is made up of a variety of cells involved in
the propagation of the inflammatory process. Hepatocytes
represent 60-80% of the total liver cell population and are
responsible for the metabolic process, biosynthesis,
biliary secretion, and detoxification. Apart from these, in
the liver, there are also cells with a role in immunity, such
as Kupffer cells (KC) responsible for innate immunity,
macrophages, and natural killer (NK) cells. After liver
injury, other cells are recruited. Some examples are
neutrophils, leukocytes, monocytes, and macrophages,
also responsible for the innate immune response. The
acquired immune response belongs to T NK cells and B
cells. Other cell types that contribute to the production of
inflammation and fibrosis are hepatic stellate cells (HSC)
and sinusoidal endothelial cells (5).
Toll-like receptors (TLRs) and interleukin 17 (IL-17)
In the liver, TLRs are expressed through Kupffer cells,
hepatocytes, stellate cells, and sinusoidal endothelial
cells. They are found in different cellular locations. TLR
2, 4, 5, 6, and 11 have extracellular location, while TLR
3, 7, 8, and 9 are expressed intracellularly in endosomes,
lysosomes, and the endoplasmic reticulum (6). TLR 4 is
the most studied TLR (7). From the family of ten TLRs
discovered in humans, TLR4 was the first to be identified
(8).
IL-17 is the generic name for a cytokine family
composed of 6 members (IL-17A, IL-17B, IL-17C, IL-

17D, IL-17E and IL-17F). Interleukin 17A, which names
the family, is secreted in the skin, liver, and mucous
membranes (9).
NASH pathogenesis
The theory of the two aggressions or the theory of
multiple hepatic aggressions has been formulated. The
first aggression in NASH is caused by modifications in
the metabolism of fatty acids, which leads to
accumulation of lipids in hepatocytes and to the
occurrence of hepatic steatosis. Lipopolysaccharides
(LPSs), oxidative stress, cytokine production, and other
pro-inflammatory mediators represent the second
aggression that sustains the progression of steatosis to
steatohepatitis (10).
Obesity and NASH pathogenesis
Adipose tissue is considered to have an endocrine and
immunological function (11).
The incidence of overweight and obesity has increased
worldwide, from 857 million in 1980 to 2.1 trillion in
2013 (12). Obesity is associated with atherosclerosis in
cardiovascular diseases, Alzheimer's disease, type-2
diabetes mellitus, and metabolic syndrome (13). The
incidence of metabolic syndrome is continually
increasing, because of unhealthy lifestyle changes in the
general population – an increasing consumption of fast
foods, high-fat diets and processed foods, a sedentary life
style, and lack of physical exercise (14).
In obesity, there is dysfunctional adipose tissue
resulting from the infiltration of macrophages and
hypertrophic adipocytes (15). The liver is the major target
for adipose tissue accumulation and, thus, the occurrence
of steatohepatitis. Therefore, adipose tissue is considered
to have a major role in NASH.
Different studies conducted on laboratory mice with
obesity have shown that pro-inflammatory pathways are
activated in the fat tissue in both obesity and NASH.
Their activation involves a multifactorial process and
includes the presence of oxidative stress which leads to
hypoxia and adipocytes death (16), changes in the
intestinal
microbiota
with
increased
intestinal
permeability, and metabolic endotoxemia (17, 18).
Obesity and NAFLD progression are associated with
dysbiosis in the intestinal microbiota (19). Furthermore,
experimental studies on animal models with diet-induced
obesity have shown that intestinal microbiota is essential
in the development of obesity and that it could play an
important role in modulating NAFLD progression (20).
Two of the most common mechanisms in NASH
pathogenesis involve the immune and inflammatory
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pathways. The inflammatory pathways are represented by
cytokines with a pro-inflammatory role (interleukins (IL),
while increased free fatty acid (FFA) concentration or
bacterial products (lipopolysaccharide-LPS) activate the
innate immune system from adipocytes and macrophages
through Toll-like receptors (TLRs) (Figure 1) and
ultimately lead to inflammation (18). Also, the increasing
level of free fatty acids in blood circulation leads to their
growth in the portal system, thus contributing to the
development of NAFLD or NASH (15).

Figure 1. Toll-like receptor (TLR) activation
As a consequence of activating the above proinflammatory pathways, adipocyte death occurs,
producing cytokines and chemokines with a key role in
the inflammatory process. Also, as a secondary
consequence, other immune cells are recruited:
neutrophils, eosinophils, dendritic cells, natural-killer
(NK) cells, T cells, B cells etc. (13).
Changes in the intestinal microbiota, TLR pathways
and NASH pathogenesis
One of the main concerns of the scientific community
is the role of intestinal microbiota and probiotics in liver
diseases. It is known that patients with NAFLD present an
increase in intestinal permeability and an increased
incidence of bacterial development in the small intestine
compared to patients without liver disease (21). Bacterial
translocation promotes the inflammatory process of the
liver by activating TLRs (22). There are two known
patterns for TLR activation: pathogen-associated
molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPs).
PAMPs originate from certain exogenous pathogens
responsible for the emergence of inflammation and
contain lipids, lipoproteins, nucleic acids, and proteins.
They are expressed by bacteria, viruses, parasites, and
fungi (6). This pathway contributes to the inflammatory
process in NASH by signaling the pathogen recognition
receptors (PRRs), leading to the activation of innate and
acquired immune systems. PAMPs are recognized by
numerous PRRs receptors, including Toll-like receptors
(TLRs) (6).
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DAMPs, similar to PAMPs, are endogenous
molecules released by destroyed cells that trigger a sterile
inflammatory response. In NASH, there is chronic
inflammation resulting from the presence of DAMP.
Similar to PAMPs, DAMPs activate both types of
immunity, i.e., acquired and innate, and PRRs, out of
which the most characteristic are TLRs (23). The DAMP
receptors responsible for TLR activation are hyaluronic
acid, fibrinogen, and thermal shock proteins (23).

Figure 2. TLRs recognize a wide range of PAMPs.
Once a molecular pattern has been recognized by
TLR, it initiates signals with a role in activating the
inflammatory and antiviral responses. Some
examples are the activation of the Kappa B Nuclear
transcription factor (NF-kb) and the regulatory
factors of interferon which determine the
transcription of inflammatory cytokines, chemokine
or type-1 interferon (6)
Different studies have attempted to elucidate the role
of TLR4 in NASH. Patients or laboratory mice with
NASH presented
increased serum levels of
polysaccharides, which would suggest an increased
activation of TLR4 (24). It is also supposed that fructose
could increase activation of TLR4 by its influence on
microbiota and intestinal permeability. It is a risk factor
for steatosis and steatohepatitis (25).
The activation of TLR4 and sensitization of hepatic
stellate cells could be the key connection between the
inflammatory process and the emergence of fibrosis in
NASH or other forms of chronic hepatitis. The
explanation could be the involvement of hepatic stellate
cells in regulating the extracellular matrix and the
regeneration of liver tissue (8).
Immune cells and IL-17 contribution to NASH
pathogenesis
The innate immune response, consisting of Kupffer
cells (KC), neutrophils, dendritic cells (DCs), and natural
killer cells (NKT) plays an important role in the
pathogenesis of NASH in NAFLD (26). Having
characteristics of both innate and acquired immune cells,
NKTs are considered to be the link between the two
immune systems. NKTs are found predominantly in the
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liver and regulate the immune response through the
secretion of cytokines TH1 and TH2 (27). T helper 17
cells (TH17) are a subdivision of T cells that secrete IL17 and play a role in mediating the immune response by
modulating the clearance of pathogens and the
inflammatory response of tissues.
In acute or chronic liver disease, KCs are activated by
PAMPs and DAMPs and release cytokines with proinflammatory roles, such as tumor necrosis factor (TNFa),
interleukin-6 (IL-6), and interleukin-1b (IL-1b),
responsible for the activation of T cells, stellate cells
which eventually lead to apoptosis (26). The activation of
neutrophils determines the release of pro-inflammatory
cytokines and myeloperoxidase responsible for the
occurrence of oxidative stress in the liver (28). Neutrophil
high concentrations compared to lymphocytes have a role
in the progression of NASH (29). A decrease in DCs
results in the unfavorable evolution of NASH, suggesting
that DCs play an important role in steatohepatitis (30).
Natural killer T cells (NKT) are a subdivision of
lymphocytes presenting markers for NK cells: CD161 and
CD94 and T cell receptors (27).
Recent studies have shown the importance of TH17
cells in autoimmune liver disease, viral hepatitis,
alcoholic steatohepatitis, and hepatocarcinoma (31). Tang
et al. (32) demonstrated an increase in the number of
TH17 cells at the hepatic level after 8 weeks of
hypercaloric diet as well as the fact that these cells are
associated with the progression of hepatic steatosis and
inflammation through the production of Interleukin 17
(IL-17).
A delayed or ineffective immune response results in
viral, bacterial, or fungal infections. But a heightened
response can be harmful, as observed in autoimmune
diseases: rheumatoid arthritis, type-1 diabetes, psoriasis,
and inflammatory bowel diseases (33). The pathogenesis
of these autoimmune disorders is related to the excessive
production of pro-inflammatory cytokines: TNF-alpha,
IL-6, IFN-gamma, IL-23 etc. (34).

claims that under the action of certain stimuli, ThCD4 +
lymphocytes are differentiated in TH1 lymphocytes and
TH2 lymphocytes. It has recently been found that under
the influence of IL-23, ThCD4 + lymphocytes
differentiate in a specific cell type whose main action is to
release IL-17, in addition to tumor necrosis factor (TNF)
and granulated monocyte colonies stimulation factor
(GM-CSF) (9). The lymphocytes of this distinct subset of
TH1 and TH2 were called Th17 lymphocytes. Apart from
Th17 lymphocytes, additional synthesis sources of IL-17
are lymphocytes THCD8 + neutrophils, NK and NKT
cells, macrophages etc. (36). Increased levels of IL-17A
were discovered in liver disorders such as alcoholic
steatohepatitis (37), viral hepatitis B and C (9, 38),
primary biliary cirrhosis (39), hepatocellular carcinoma
(40). The increased expression of IL-17A is also found in
patients with obesity and is associated with an increased
infiltration of adipose tissue with TH17 (41).

Conclusions
One of the possible mechanisms responsible for the
activation of the immune system through intestinal
microbiota is the activation of IL17 axis. The other one is
the activation of the TLRs. Further studies are necessary
to test these possibilities.
The elucidation of mechanisms underlying the
progression of hepatic steatosis towards steatohepatitis is
essential for the development of useful diagnosis and
treatment for medical practice.
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